Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Burkina Faso forces killed twice as many civilians as jihadists, rights group says - 2Vote in favor of the juice that you love for its medical advantages!
- 3Pick Your #1 Japanese Food
- 4The 10 Most Famous Style Minutes on Honorary pathway
- 5Colombia's military rescues 6 siblings who hid in the rainforest to escape from a rebel group
- Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
- Bad flu season getting worse; skyrocketing cases set state record
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- How did birds survive while dinosaurs went extinct?
- France to build new nuclear aircraft carrier, Macron says
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Watch Chinese astronauts enjoy '1st ever space BBQ' from Tiangong's brand-new oven (video)
- EU top diplomat Kallas arrives in Kiev to commemorate Bucha massacre
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
